StockNews.AI
RXST
StockNews.AI
27 days

RxSight, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Portnoy Law Firm investigates RxSight for possible securities fraud. 2. Class action lawsuit alleges misleading statements and poor sales performance. 3. RxSight revised 2025 revenue guidance down by $42.5M midpoints. 4. Company faced adoption challenges affecting product utilization and sales. 5. Shares dropped nearly 38% following negative financial disclosures.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The class action lawsuit and substantial share decline suggest severe investor distrust. Historical patterns indicate that similar allegations often lead to prolonged stock price decreases.

How important is it?

Legal investigations can severely impact investor confidence and stock value, as numerous class action cases have led to lasting undervaluations.

Why Short Term?

The immediate reaction to the lawsuit and financial performance will likely dominate market sentiment. If unresolved, negative sentiment could persist in the short run.

Related Companies

ALGNNUVAISRG
Investors can contact the law firm at no cost to learn more about recovering their losses​ LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. RxSight investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company specializing in the development, manufacturing, and commercialization of light adjustable intraocular lenses (LALs), which are used in cataract surgery. According to the class action lawsuit, throughout the Class Period, RxSight and its executives made materially false and/or misleading statements and/or failed to disclose critical information, including that: The company was experiencing adoption challenges and underlying structural issues that were negatively impacting sales and product utilization;RxSight had overstated market demand for its products; andAs a result, the company was unlikely to meet its previously issued financial guidance for fiscal year 2025. The lawsuit further alleges that on July 8, 2025, RxSight issued its preliminary Q2 2025 financial results, revealing significant declines in sales of its Light Delivery Devices (LDDs), reduced LAL utilization, and lower overall revenue. In addition, RxSight revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint. During the corresponding investor communication, RxSight’s CEO, Ronald Kurtz, acknowledged that “adoption challenges over the last few quarters have been a primary reason for the LDD stall.” Following this disclosure, shares of RxSight declined by nearly 38%, according to the complaint. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News